May 14th 2024
Dynavax is currently reviewing FDA feedback and strategizing a meeting to discuss their HEPLISAV-B 4-dose regimen for hemodialysis patients, determining the path forward toward approval.
Hepatitis B Prevention: We Have the Vaccines, But Not the Implementation
February 22nd 2023Despite effective vaccines and other prevention and treatment modalities, hepatitis B remains a global health challenge. “It’s not for the lack of available tools,” says professor and hepatologist H. Nina Kim, MD, MSc.
Read More
Conversations Around Diagnosing HIV, Shaping Treatment Expectations
February 20th 2023A clinician offers insights on the initial conversations around learning to treat a chronic disease and the importance behind getting patients started down the right treatment path in the early days following a diagnosis.
Read More
HBV Infection Linked to Threefold Increase in Fibrosis in Patients with Liver Disease
February 17th 2023A recent study suggests that metabolic factors such as hypertension and diabetes were associated with an increased risk of liver fibrosis among patients with metabolic associated fatty liver disease who had hepatitis B virus infection.
Read More